Inhibition of neointimal hyperplasia development by MCI-186 is correlated with downregulation of nuclear factor-κB pathway

Circulation Journal

Volumn 72, Issue 5, 2008, Pages 800-806

  Radhakrishnan, Geethalakshmi ^a   Suzuki, Ryoko ^a   Maeda, Hironori ^a   Yamamoto, Morio ^a   Hirose, Nobuyuki ^a   Gopalrao, Rajesh Katare ^a   Lee, Gang Hang ^a   Hayashi, Yoshihiro ^a   Rao, Parijatha ^a   Sasaguri, Shiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Antioxidants; Atherosclerosis; Free radicals

Indexed keywords

CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPID; NORPHENAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTERY INTIMA PROLIFERATION; ARTICLE; ATTENUATION; CELL PROLIFERATION; CHOLESTEROL DIET; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIUM CELL; FEEDING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; JAPANESE; LIPID STORAGE; MACROPHAGE MIGRATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER; SUBENDOTHELIUM; UMBILICAL VEIN; WESTERN BLOTTING;

ANGIOPLASTY, BALLOON; ANIMALS; ANTIOXIDANTS; ANTIPYRINE; CAROTID ARTERY DISEASES; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CHOLESTEROL; DISEASE MODELS, ANIMAL; DOWN-REGULATION; E-SELECTIN; FREE RADICAL SCAVENGERS; HYPERPLASIA; I-KAPPA B PROTEINS; INTERLEUKIN-1BETA; MALE; NF-KAPPA B; RABBITS; SIGNAL TRANSDUCTION; SUPEROXIDES; TUNICA INTIMA;

EID: 44149099762     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.800     Document Type: Article

References (32)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809.
2. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Lusis A. Atherosclerosis. Nature 2000; 407: 233-241.
5. Schwartz S. The Iitima: A new soil. Circ Res 1999; 85: 877-879.
6. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003; 83: 1069-1112.
7. Linton M, Fazio S. Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S35-S40.
8. Schwartz S. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997; 99: 2814-2816.
9. Madamanchi N, Vendrov A, Runge M. Oxidative stress and vascular disease. Atheroscler Thromb Vasc Biol 2005; 25: 29-38.
10. Sasu S, Beasley D. Essential roles of IκB kinases α and β in serum-and IL-1-induced human VSMC proliferation. Am J Physiol Heart Circ Physiol 2000; 278: H1823-H1831.
11. DeWinther M, Kanters E, Kraal G, Hofker M. Nuclear factor κB signaling in atherogenesis. Atheroscler Thromb Vasc Biol 2005; 25: 904-914.
12. May MJ, Ghosh S. Rel/NF-κB and IκB proteins: An overview. Cancer Biol 1997; 8: 63-73.
13. Monaco C, Paleolog E. Nuclear factor κB: A potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671-682.
14. Jawien J, Gajda M, Mateuszuk L, Olszanecki R, Jakubowski A, Szlachcic A, et al. Inhibition of Nuclear factor-κB attenuates atherosclerosis in apoE/LDLR-Double knockout mice. J Physiol Pharmacol 2005; 56: 483-489.
15. Hayashi K, Takahata H, Kitagawa N, Kitange G, Kamingo M, Shibata S. N-acetyl cysteine inhibited nuclear factor-kappa B expression and the intimal hyperplasia in rat carotid arterial injury. Neurol Res 2001; 23: 731-738.
16. Yamamoto Y, Kuwahara T, Watanabe K. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep 1996; 2: 333-338.
17. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazohn-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 2006; 1: 85-93.
18. Suzuki R, Katare Gopalrao R, Maeda H, Rao P, Yamamoto M, Xing Y, et al. MCI-186 inhibits tumour growth through suppression of EGFR phosphorylation and cell cycle arrest. Anticancer Res 2005; 25: 1131-1138.
19. Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988; 33: 81-87.
20. Okabe T, Kishimoto C, Shimada K, Murayama T, Yokode M, Kita T. Effects of MCI-186 (edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J 2006; 70: 1216-1219.
21. Xu Q. Mouse model of arterioslerosis: From arterial injuries to vascular grafts. Am J Pathol 2004; 165: 1-10.
22. 2+ transients. Circ Res 1999; 85: 515-523.
23. Wada Y, Sugiyama A, Kohro T, Kobayashi M, Takeya M, Naito M, et al. In vitro model of atherosclerosis using coculture of arterial wall cells and macrophage. Yonsei Med J 2000; 41: 740-755.
24. Guzik TJ, West NE, Pillai R, Taggart DP, Channon KM. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002; 39: 1088-1094.
25. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1488.
26. Dong Z, Chapman S, Brown A, Frenette P, Hynes R, Wagner D. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998; 102: 145-152.
27. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436-1439.
28. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
29. Violi F, Micheletta F, Luliano L. Antioxidants and atherosclerosis. Eur Hart J Suppl 2002; 4: B17-B21.
30. Shah PK. Inflammation, neointimal hyperplasia, and restenosis: As the leukocytes roll, the arteries thicken. Circulation 2003; 107: 2175-2177.
31. Popma JJ, Berger P, Ohman M, Harrington RA, Grines C, Weitz J. Antithrombotic therapy during percutaneous coronary intervention. Chest 2004; 126: 576S-599S.
32. Morita H, Saito Y, Ohashi N, Yoshikawa M, Katoh M, Ashida T, et al. Fluvastain ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: The antioxidative properties of fluvastatin. Circ J 2005; 69: 475-480.